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Microglia, glial cells with immunological functions, have been implicated in various
neurological diseases and psychiatric disorders in rodent studies, and human
postmortem and PET studies. However, the deeper molecular implications of living
human microglia have not been clarified. Here, we introduce a novel translational
research approach focusing on human microglia. We have recently developed a new
technique for creating induced microglia-like (iMG) cells from human peripheral blood.
Two cytokines, GM-CSF and IL-34, converted human monocytes into the iMG cells
within 14 days, which show various microglial characterizations; expressing markers,
forming a ramified morphology, and phagocytic activity with various cytokine releases.
We have already confirmed the applicability of this technique by analyzing iMG cells
from a patient of Nasu-Hakola disease (NHD; Ohgidani et al., 2014). We herein
show possible applications of the iMG cells in translational research. We believe
that this iMG technique will open the door to explore various unknown dynamic
aspects of human microglia in psychiatric disorders. This also opens new routes for
psychopharmacological approach such as drug efficacy screening and personalized
medicine.
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disorders, GM-CSF, IL-34
Recently, the roles of microglia, immune cells in the brain, have been highlighted not
only by neuroscientists but also by a variety of clinical researchers, especially in the field
of neurology and psychiatry (Hughes, 2012). The pathophysiology of microglia has been
suggested in various neuronal diseases and psychiatric disorders by human postmortem
and positron emission tomography (PET) studies (Steiner et al., 2008; van Berckel et al.,
2008; Takano et al., 2010; Gupta et al., 2014). Furthermore, microglial modulation has
been proposed as an intervention in brain diseases including psychiatric disorders by
recent clinical trials using minocycline, an antibiotic with microglial inhibitory effects
(Miyaoka et al., 2008; Levkovitz et al., 2010; Chaudhry et al., 2012; Hayakawa et al.,
2014). It has also been suggested that minocycline acts to modulate social interactions
not only in psychiatric patients but also in healthy volunteers (Kato et al., 2012; Watabe
et al., 2012, 2013). On the other hand, various psychotropic drugs have been revealed to
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FIGURE 1 | Induced Microglia-like Cells (iMG) from Human Peripheral Blood.
inhibit microglial over-activation in in vitro experiments using
rodent cells (Kato et al., 2007, 2008, 2011a,b; Bian et al., 2008;
Seki et al., 2013).
The above reports have strongly suggested that maladaptive
microglial activation may play a crucial role in various brain
disorders (Block et al., 2007; Hanisch and Kettenmann, 2007;
Kato et al., 2013). However, the deeper dynamic molecular
actions of living human microglia in real patients have not
been well clarified due to technical and ethical issues (such
as difficulties involved in human brain biopsies). Until now,
almost all human microglia research has been conducted using
the postmortem brain or PET. These approaches have revealed
important roles for activated microglia in psychiatric patients
such as schizophrenia and autism (Steiner et al., 2008; van
Berckel et al., 2008; Takano et al., 2010; Suzuki et al., 2013;
Gupta et al., 2014). However, using these methods, it is
difficult to ascertain the molecular pathological mechanisms
such as the signaling pathway and gene expression pattern.
On the other hand, animal (rodent) studies with cytological
and histological analysis can reveal the various deeper dynamic
actions of microglia at molecular levels (Nimmerjahn et al.,
2005; Wake et al., 2009; Kettenmann et al., 2011). In fact,
microglial activation has been shown in a variety of cytological
and histological analyses using rodent models of brain diseases
(Wu et al., 2002; Yoshiyama et al., 2007). Molecular biological
analysis using rodent primary cultures and cell strains has
been the standard method until now (Kato et al., 2007,
2008, 2011a,b; Bian et al., 2008; Seki et al., 2013; Mizoguchi
et al., 2014a,b). In fact, rodent studies have been very vital in
microglial research, however the question remains- how much
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does human pathology reflect in rodents? Can schizophrenia
model mice have delusions and/or hallucinations? Even though
a variety of rodent models of psychiatric disorders exist, it
is extremely hard to validate deeper psychopathologies in
rodents.
Thus, human studies using living brain cells derived from
psychiatric patients have been warranted to evaluate the
interactions of microglial activities and deeper psychopathology
including psychiatric symptoms. A novel term ‘‘cellular model’’
has emerged in addition to ‘‘animal model’’ in the research
of various physical diseases. The technology to obtain human
neuronal cells from non-brain tissues (e.g., skin) by novel
reproductive techniques such as induced pluripotent stem
(iPS) cells (Takahashi et al., 2007) and directly induced
neuronal (iN) cells (Pang et al., 2011; Liu et al., 2013) has
emerged, and these tools have just recently been applied
to psychiatric research (Kim, 2010; Brennand et al., 2011;
Wen et al., 2014). Further, iPS technology can produce
glial cells such as astrocytes (Juopperi et al., 2012) and
progenitor of oligodendrocytes (Wang et al., 2013). However,
to our knowledge, there exist no reports on the production
of microglia by iPS technology. Very recently, we have
developed a novel technique to create induced microglia-like
cells (iMG) from human peripheral blood (Ohgidani et al.,
2014).
The brain is mostly composed of ectomorphic cells such
as neurons, astrocytes and oligodendrocytes. Microglia is the
only mesomorphic cell in the brain (Kettenmann et al.,
2011). Therefore, we tried to induce microglia-like cells
from peripheral monocytes, which have the same origin as
mesomorphic cells. To determine what cytokines can induce
iMG cells from human peripheral monocytes, we tested
the effects of cytokines. Surprisingly, the cocktail of both
granulocyte-macrophage colony-stimulating factor (GM-CSF)
and interleukin (IL)−34 successfully induced small soma bodies
bearing numerous branched collaterals, which expressed the
specific morphology of ramified microglia-small soma with
extensive radial ramifications. The iMG cells express the essential
characteristics of human microglia such as surface markers
and drug responses, phagocytosis and cytokine production
(Figure 1).
We first utilized the iMG cells as a ‘‘cellular disease model’’
focusing on one of the most famous primary microglia-
oriented diseases, the Nasu-Hakola disease (NHD; Hakola,
1972; Nasu et al., 1973). NHD is a very rare autosomal
recessive disease, and the responsible two genes, which are
expressed in microglia in the brain, are DNAX-activation protein
of 12 kDA (DAP12) and triggering receptor expressed on
myeloid cells 2 (TREM2; Paloneva et al., 2000, 2002). The
deeper pathophysiological roles of microglia have not been
well understood. Thus, we investigated the pathophysiology of
NHD using the iMG technique. In agreement with genetic
diagnosis, the iMG cells from a NHD patient (141delG in
DAP12 gene) showed significantly lower expression of DAP12
than those from a healthy control (HC). Interestingly, the
response of producing pro-inflammatory cytokines (TNF-α
and IL-6) was delayed in the iMG cells from the NHD
patient as compared to those from HC. Furthermore, we
have also confirmed the delayed cytokine productions in the
NHD model of iMG cells which was prepared by siRNA
(Ohgidani et al., 2014). These novel findings may help to
understand the hitherto unknown pathophysiological aspects
of NHD.
In this way, we believe that the iMG technique will enable
the clarification of novel pathophysiological dysfunctions of
human microglia as a translational research tool in various brain
diseases including psychiatric disorders. We believe that the
iMG technique will enable the exploration and development of
psychiatric research especially to the following areas;
Multidimensional Correlation Analysis with
Clinical Data, Brain Imaging Data and iMG
By combining clinical data, brain imaging data, and the iMG
data from the same patient will be able to clarify the dynamic
interaction between a specific psychopathology and a specific
microglial activation (Figure 2-(1)). For example, the aberration
of TREM, which is expressed in microglia, has recently been
observed in psychiatric disorders such as bipolar disorder
(Weigelt et al., 2011) and Alzheimer’s disease (Jonsson et al.,
2013). Analyzing the TREM aberration of iMG cells from
psychiatric patients can help to clarify the main role of TREM
in psychopathology, which in turn may assist in the psychiatric
evaluation of diagnosis and severity.
Drug Evaluation and Personalized
Medicine
We previously reported the neuroprotective effects of
psychotropic drugs via suppressing microglial activation
using rodent microglial cells (Kato et al., 2007, 2008, 2011a,b;
Bian et al., 2008; Seki et al., 2013). The iMG technique may
help to predict drug responses before treating patients. Drug
efficacy screening using iMG cells can predict which drug will
FIGURE 2 | Utilities of the iMG cells in Psychiatry Translational
Research.
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respond best to each respective patient, and the technique may
be applied as a companion diagnostic tool, which has raised
expectations for the application of ‘‘order-made’’ medicine with
a reduction in side effects and a shortening of treatment period
(Figure 2-(2)).
Conclusion
We introduced a novel translational research approach focusing
on human microglia-like cells using the iMG technique.
Before reaching a conclusion, we need to mention a recent
considerable discussion regarding functional differences between
yolk sac derived microglia and monocyte derived microglia
(Ginhoux et al., 2010; Katsumoto et al., 2014). We should
keep it in our mind that the iMG cells are originated from
monocytes, which may be different from the functions of yolk
sac derived microglia. In addition, because IL-34 is a tissue-
restricted ligand of CSF1R and this cytokine is associated
with the development of other types of monocyte-derived
cells such as Langerhans cells and possibly dendritic cells
(Wang et al., 2012), which should also be considered. Despite
these propositions, we believe that the iMG technique, at
least to some extent, can analyze human microglial pathology
in a living state, which had been impossible until recently.
We hope that this translational method will open the door
to explore various unknown dynamic aspects of human
microglia in brain diseases, especially psychiatric disorders.
This opens new routes for not only understanding the
psychopathological mechanism of psychiatric disorders but also
psychopharmacological approach such as drug efficacy screening
and personalized medicine.
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